| GTO ID | GTC2433 |
| Trial ID | NCT04520711 |
| Disease | Epithelial Cancer |
| Altered gene | Neoantigen |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Neoantigen TCR-T cells |
| HLA | unspecified |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) Targeting Tumor-Specific Neoantigens, With in Vivo CD40 Activation and PD-1 Blockade, for Patients With Incurable Cancers (2020000584) |
| Year | 2020 |
| Country | United States |
| Company sponsor | Providence Health & Services |
| Other ID(s) | 2020000584 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||
|
|||||||||||